Register for streaming realtime charts, analysis tools, and prices.
Period:
Draw Mode:
| Volume | 5 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Tenaya Therapeutics Inc | TNYA | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 4.38 | 04:05:10 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.38 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 5 | - | 1.66 - 8.0914 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:00:00 | 5 | $ 4.38 | USD |
Tenaya Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 298.33M | 68.11M | - | 0 | -124.08M | -1.82 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Tenaya Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical TNYA Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.29 | 4.69 | 4.14 | 4.36 | 292,113 | 0.09 | 2.10% |
| 1 Month | 5.16 | 5.32 | 4.14 | 4.56 | 301,335 | -0.78 | -15.12% |
| 3 Months | 4.28 | 7.01 | 4.11 | 5.26 | 545,497 | 0.10 | 2.34% |
| 6 Months | 1.97 | 7.01 | 1.66 | 4.19 | 480,736 | 2.41 | 122.34% |
| 1 Year | 5.78 | 8.0914 | 1.66 | 4.69 | 475,154 | -1.40 | -24.22% |
| 3 Years | 19.50 | 32.00 | 1.64 | 6.26 | 317,790 | -15.12 | -77.54% |
| 5 Years | 19.50 | 32.00 | 1.64 | 6.26 | 317,790 | -15.12 | -77.54% |
Tenaya Therapeutics Description
| Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine. |
